首页> 外文期刊>Journal of the International Association of Providers of AIDS Care. >Systemic Delays in the Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients in Houston, Texas
【24h】

Systemic Delays in the Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients in Houston, Texas

机译:在得克萨斯州休斯敦临床合格的HIV感染患者开始抗逆转录病毒疗法的系统性延误

获取原文
获取外文期刊封面目录资料

摘要

The current US HIV treatment guidelines support initiation of antiretroviral therapy (ART) for persons with HIV for personal health benefits and prevention of HIV transmission. However, high levels of adherence to ART are critical to maximize individual and public health benefits. We examined the nonclinical barriers to ART initiation for clinically eligible individuals and the provider- and patient-related factors associated with these barriers among HIV-infected patients in Houston/Harris County, Texas. We analyzed data obtained from a probability sample of HIV medical care providers (HMCPs) in 13 outpatient facilities in Houston/Harris County, Texas surveyed between June and September 2009. We used an inductive thematic approach to code HMCP responses to an open-ended question that asked the main reasons why providers may delay initiating ART for clinically eligible patients. The reasons cited by providers for delaying ART for clinically eligible patients were adherence (42.5%; 95% confidence interval [CI]: 28.5-57.8), acceptance (30%; 95% CI: 18.1-45.4), and structural concerns (27.5%; 95% CI: 16.1-42.8), with significant variations (P P = .039) and 10 times (aOR: 10.36; 95% CI: 1.42-22.70; P = .019) more likely to state adherence and acceptance concerns, respectively, as reasons for delaying ART for clinically eligible patients. Our findings highlight the fact that clinical guidelines are only a starting point for medical decision-making process and that patients themselves play an important role. HMCP access to referrals for other medical issues, support services, and treatment education may help improve adherence and patient readiness for ART, thereby avoiding systemic delays.
机译:当前的美国艾滋病毒治疗指南支持为艾滋病病毒感染者启动抗逆转录病毒疗法(ART),以实现个人健康利益并预防HIV传播。但是,高水平的抗逆转录病毒疗法对最大程度地提高个人和公共健康利益至关重要。我们在得克萨斯州休斯敦/哈里斯县,对临床上有资格的个体进行抗病毒治疗的非临床障碍以及与这些障碍相关的提供者和患者相关因素进行了研究。我们分析了从2009年6月至9月在德克萨斯州休斯顿/哈里斯县的13个门诊设施中的HIV医疗服务提供者(HMCP)的概率样本中获得的数据。我们使用归纳主题方法对HMCP对开放式问题的回答进行编码这就询问了提供者为什么可能会延迟临床合格患者的抗病毒治疗的主要原因。提供者提到延迟临床合格患者接受抗逆转录病毒治疗的原因是依从性(42.5%; 95%可信区间[CI]:28.5-57.8),接受度(30%; 95%CI:18.1-45.4)和结构性担忧(27.5) %; 95%CI:16.1-42.8),且有较大的差异(PP = .039)和10倍(aOR:10.36; 95%CI:1.42-22.70; P = .019)更有可能说明遵守和接受的问题,分别作为延迟临床合格患者抗逆转录病毒治疗的原因。我们的发现突出了这样一个事实,即临床指南只是医疗决策过程的起点,而患者本身起着重要作用。 HMCP可以就其他医疗问题,支持服务和治疗教育转介患者,这可能有助于提高依从性和患者对ART的准备程度,从而避免系统性延误。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号